Quantum Immunlogics
Upcoming SlideShare
Loading in...5
×
 

Quantum Immunlogics

on

  • 881 views

Quantum Immunologics (QI) is dedicated to the research, development and production of products and services that will promote immunologic cancer treatments and cancer detection technologies.

Quantum Immunologics (QI) is dedicated to the research, development and production of products and services that will promote immunologic cancer treatments and cancer detection technologies.

Statistics

Views

Total Views
881
Views on SlideShare
878
Embed Views
3

Actions

Likes
1
Downloads
17
Comments
0

3 Embeds 3

http://www.slideshare.net 1
http://naturalhealthreviews7.com 1
http://www.slideee.com 1

Accessibility

Upload Details

Uploaded via as Microsoft PowerPoint

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment
  • The OFA antigen is found not only on breast cancer, but on many other cancers including lung, liver and renal. In fact, OFA has been found on every mammalian cancer that has been studied according to a paper published in the Journal of Modern Aspects of Immunobiology
  • Important to recognize that it was the FDA that kicked QI into a Phase II trial. The initial application was only for a Phase I trail, but the FDA “suggested” that QI go ahead and do a Phase II trial as well.
  • And recall that QI has the exclusive license for other countries beside just the US. So when you look at the unmet medical need worldwide…it’s huge.
  • If QI’s immuno-therapy approach for Stage IV breast cancer patients, it is logical to start to utilize the QI immuno-therapy approach for all breast cancer patients, given the much more favorable side effects profile. And the market for all breast cancer patients is BEYOND HUGE.
  • QI’s R&D staff continue to work on finding even better approaches to combating cancer.
  • Anti bodies stick to the peptides found on OFA Given that OFA appears to be a universal cancer marker, these antibodies can be “tagged” with chemical or radiological markers to detect the presence of OFA/cancer in tissue and blood.
  • QI has accomplished much in a short amount of time.
  • One of the interesting aspects of QI is their use of Independent Contractors. Most of the above folks are independent contractors who have been working for QI stock. QI recognizes that as QI evolves, QI knows that many of these independent contractors will have to come on board as traditional, full time employees. But this approach has allowed QI to conserve capital.

Quantum Immunlogics Quantum Immunlogics Presentation Transcript

  • Fighting Cancer With Leading Edge Immunotherapy November 2009
    • Mission Statement
    • Putting Cancer Into Context
    • Immunotherapy Overview & QI’s Approach
    • QI’s Immunotherapy Video
    • FDA Authorized Phase I/II Trials
    • Economic Perspective
    • QI’s Ongoing Research & Development
    • About QI
    • An investment in QI is speculative, involves a high degree of risk and is suitable for persons of substantial means who have no need for liquidity with respect to their investment and can bear such risks, including the risk of losing their entire investment. Any investor considering making a potential investment in QI needs to read and review the “Private Placement Memorandum for Quantum Immunologics, Inc.,” particularly the “Risk Factors” section.
    Quantum Immunologics (QI): Agenda 3 4 7 10 12 15 18 11
  • Quantum Immunologics (QI) is dedicated to the research, development and production of products and services that will promote immunologic cancer treatments and cancer detection technologies that are: All at greatly reduced and highly competitive costs. Mission Statement
    • Individualized
    • Targeted
    • Safe
    • Highly efficacious
  • Putting Cancer Into Context: Recent News Articles
    • New York Times Article, April 24, 2009 entitled “Forty Years’ War: Advances Elusive in Drive to Cure Cancer”
      • “ Cancer has always been an expensive priority. Since the war on cancer began, the National Cancer Institute…has alone spent $105 billion. And other government agencies, universities, drug companies and philanthropies have chipped in uncounted billions more.”
      • “ Yet the death rate for cancer, adjusted for size and age of the population dropped only 5% from 1950 to 2005. In contrast, the death rate for heart disease dropped 64% in that time.”
      • “ With breast cancer…only 20% with metastatic disease – cancer that has spread outside the breast, like to bones, lungs, or liver – live five years or more, barely changed since the war on cancer began.”
    • May 31, 2009 Associated Press Article “Immune Therapies Finally Working Against Cancer”
      • “ First there was surgery, then chemotherapy and radiation. Now doctors have overcome 30 years of false starts and found success with a fourth way of fighting cancer: using the body’s natural defender, the immune system.”
      • Positive late stage clinical results have been obtained for:
        • Prostate cancer
        • Brian cancer
        • Small cell lung cancer
    Putting Cancer Into Context: Recent News Articles (cont.)
    • Time Magazine Article, September 14, 2009: “A Shot at Cancer”
        • “ It’s been a slow evolution, but we are seeing the first inklings that cancer vaccines can work,” says Dr. Steven Rosenberg, chief of the surgery branch at the National Cancer Institute.
        • “ Understanding how the immune system works is going to play a significant role in our treatment of cancer going forward” says Dr. Len Lichtenfeld of the American Cancer Society.
    Putting Cancer Into Context: Recent News Articles (cont.)
    • Two general approaches to immunotherapy
      • Directed against a structure vital in the replication/growth process of the cancer cell
      • Directed against a foreign protein on the cancer cell leading to cell destruction
    • Immunotherapy allows patients to have a better quality of life
      • Fewer side effects because immunotherapy targets only cancer cells, avoiding healthy tissue
    Immunotherapy Overview
    • OFA - immature form is not found on normal tissue
    • The OFA protein is found on many cancer lines
    QI’s Immunotherapy Approach: Oncofetal Antigen - Immature Laminin Receptor (OFA)
    • Sensitizes cells known as antigen presenting cells (dendritic cells) to OFA
    • Dendritic cells then present OFA to T-lymphocytes
    • T-lymphocytes are directed to combat cells that have OFA
    QI’s Immunotherapy Approach Focuses on OFA QI is the exclusive licensee of various patent rights in the U.S., Europe and other countries for the use of OFA to diagnose, monitor and treat cancer diseases
  • QI’s Process: Video of OFA / Dendritic Cell Immunotherapy
  • Design Target Population Number of Patients Treatment Primary Objectives Secondary Objectives QI’s FDA Authorized Phase I/II Trial Is Underway Multi center, open label, non-randomized Metastatic Stage IV Breast Cancer Patients, who have undergone and failed radiation and/or chemotherapy
    • 27 Total
    • Phase I - 3 patients (safety)
    • Phase II - 24 patients (safety and efficacy)
    3 OFA loaded activated dendritic cell injections, with monthly intervals between each injection
    • Determine safety and toxicity
    • Determine immunological response and induction of OFA specific T-lymphocytes
    • Evaluate objective clinical responses
    • Evaluate time to disease progression
    • Evaluate survival
  • Chemotherapy Herceptin QI ImmunoTx Micro Economic Perspective of Treatment Options for Metastatic Breast Cancer Total Cost Patient Side Effects Number of Treatments 4 – 20+ IV - Year long, every week or every 3 weeks 3 injections, monthly intervals $10,000 - $200,000 $70,000 - $100,000 $60,000 Can Be Multiple and Severe Some, and likely to be Moderate Minimal, and likely to be Mild
    • The market niche for Stage IV breast cancer only is Huge
      • The estimated number of deaths of American patients with breast cancer in 2009 is 40,610 (Source: American Cancer Society)
    Penetration Rate 10% 20% 30% 40% Macro Economic Perspective of Stage IV Breast Cancer Market Number of estimated deaths from breast cancer in 2007 worldwide is 464,854 (Source: American Cancer Society) Number of Patients (US Only) 4,061 8,122 12,183 16,244 Annual QI Rev at $60,000/Patient $243,660,000 $487,320,000 $730,980,000 $974,640,000
    • The market niche for ALL stages of breast cancer is Beyond Huge
      • The estimated number of new breast cancer cases in America in 2009 is 194,280 (Source: American Cancer Society)
    Penetration Rate 10% 20% 30% 40% Macro Economic Perspective of All Stages of Breast Cancer Number of estimated new breast cancer cases worldwide in 2007 is 1,301,867 (Source: American Cancer Society) Number of Patients (US Only) 19,428 38,856 58,284 77,712 Annual QI Rev at $60,000/Patient $1,165,680,000 $2,331,360,000 $3,497,040,000 $4,662,720,000
  • Looking Ahead: QI’s Ongoing Research & Development
      • Provisional Patent 1 : OFA peptides
        • Specific protein sequences found within OFA
        • More easily recognized and processed by dendritic cells
    QI’s Ongoing Research & Development: Two Provisional Patents Have Been Filed It may be possible to directly administer these peptides to the patient without the need for ex vivo sensitization by dendritic cells
  • This could lead to a diagnostic test for the presence of cancer in the body
      • Provisional Patent 2 : QI has discovered antibodies against specific OFA peptides
      • Antibodies are proteins made by the body’s immune system that aid in the recognition and destruction of foreign substances, including cancer cells
    QI’s Ongoing Research & Development: Two Provisional Patents Have Been Filed (cont.)
    • Historical Milestone Dates
    • Management & Science Team
    • Funding Needs
    • Capitalization - Past and Present
    • Looking Out Through 2010
    • Summary
    About QI
  • Jul Oct Jan Sep Dec Mar Apr Aug Nov Feb 2008 2009 Opened TN Lab to conduct further cancer research and immunotherapy product development Filed two provisional patent applications involving cutting-edge cancer immunotherapies and diagnostics Took control of management and operations of the AL Lab to oversee and conduct Phase I/II Trial Secured Exclusive Worldwide License Agreement for all products/patents developed by SAMSF related to OFA Begin Phase I/II Trials of immunotherapy for Stage IV Breast Cancer Patients QI’s Historical Milestone Dates May Jun QI receives FDA authorization for Phase I/II Clinical Trial for Stage IV Breast Cancer Patients Oct QI presented at the Rodman & Renshaw Global Investor Conference
    • The scientists behind the science
      • Martin Eason, MD – Chief of Industry Relations, Director
      • Kent Johnson, MD – Chief Scientific Adviser
      • Eric Olle, PhD – Director of Research
    • Chuck Broes – Chief Executive Officer & Chairman of the Board
      • Taina Broes – Chief Operating Officer
      • Josh Coughlin – Chief Investment Officer, Director
      • Barry Rooth – Chief of Corporate Affairs, Director
      • Tim Schwiers – Director of Investor Relations
      • Don Wright – Chief Financial Officer
    • Because of their belief in QI, all of QI’s management/science team is working for stock, or at reduced salaries plus stock.
    QI’s Management & Science Team
    • Round 1 Capital Raise - $5,000,000 Private Placement Memorandum
      • Used to substantially complete Phase I / II Trial
      • Used to track/monitor Phase I / II Trial results
      • Continue the R&D efforts on other cancer products
      • Plan and prepare FDA submission of Phase II b / III Trial
    • Round 2 Capital Raise / IPO / JV or Acquisition by Pharmaceutical Company - $TBD
      • To execute Phase II b / III Trial
      • Continue R&D
    QI’s Funding Needs
  • QI’s Capitalization: Past Capital Raising Initiatives Capital Raising Tranche $ per share # Warrants $ Amount Invested # Shares Issued # Warrants Issued Imputed Price per Share Tranche 1 $10 3 $ 924,100 92,410 277,230 $ 3.57 Tranche 2 $10 2 $ 2,169,712 216,971 433,942 $ 4.55 Tranche 3 $10 1 $ 1,104,720 110,472 110,472 $ 6.25 Mentor Capital * *note receivable $12 na $ 2,244,000 187,000 na $ 12.00 TOTAL: $ 6,442,532 606,853 821,644 Non-cash Shares Founders/Directors/CEO 237,757 VRI / Venturific 82,172 Total Shares Outstanding 926,782
  • QI Summary Capitalization Table (as of 9-30-09) Current Shares Current Warrants Total # Outstanding 926,782 821,644 QI Equity Capitalization $ 11,121,384 Round 1 Shares Total $ Amount $ 5,000,000 Share Price $ 12 # Shares 416,666 % of QI Outstanding 31.0% Post Round 1 Shares Total # Outstanding 1,343,448 QI Equity Capitalization $ 16,121,376
  • Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec Dec Nov Oct Phase I/II Trial Phase II b/ III Trial R&D Corp. 2009 2010 QI: Estimated Timeline Through 2010 Financing Take on FTEs Round 1 - $5mm Continue to Follow Up FDA Application/Planning Process Round 2 – IPO/Rev Merge Shell + SPO/JV/Acquisition
      • QI is the exclusive licensee of various patent rights in the U.S., Europe and other countries for the use of OFA to diagnose, monitor and treat cancer diseases
      • In addition to breast cancer, OFA is present in multiple cancer lines
      • Market niche for a successful immunotherapy treatment approach for breast cancer is several billion dollars
      • QI’s management team has accomplished much in a short amount of time with scarce resources and minimal capital
      • QI seeks additional capital to:
        • - validate QI’s immunotherapy approach in the Phase I / II trial
        • - plan and execute subsequent Phase II b / III trials
      • Significant ROI potential, with numerous avenues to a liquidity event
    QI Summary: Business Perspective
      • 1 in 8 women will be diagnosed with breast cancer
      • Despite vast amounts of research time, billions of dollars in research, and trillions of dollars in treatment, mortality rates for breast cancer are essentially unchanged
      • QI’s FDA-Authorized Phase I / II Trial for Stage IV Breast Cancer Patients is underway
      • Preliminary Phase I / II results will be known by year end 2009
      • An investment in QI is speculative, involves a high degree of risk and is suitable for persons of substantial means who have no need for liquidity with respect to their investment and can bear such risks, including the risk of losing their entire investment. Any investor considering making a potential investment in QI needs to read and review the “Private Placement Memorandum for Quantum Immunologics, Inc.,” particularly the “Risk Factors” section.
    QI Summary: Clinical Perspective
  • Fighting Cancer With Leading Edge Immunotherapy November 2009